| 1 |
Guideline [Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update] 2006
López-San Román A, Obrador A, Fortún J, Muñoz P, Gassull MA, Anonymous00201. · Servicio de Gastroenterología, Hospital Ramón y Cajal, Madrid, Spain. · Gastroenterol Hepatol. · Pubmed #16448610 No free full text.
This publication has no abstract.
|
| 2 |
Guideline [GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease] 2005
Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull MA, Anonymous00132. · Servicio de Aparato Digestivo, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. · Gastroenterol Hepatol. · Pubmed #15771858 No free full text.
This publication has no abstract.
|
| 3 |
Guideline [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis] 2003
Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA, Anonymous00002. · Servicio de Digestivo. Hospital Son Dureta. Palma de Mallorca. España. · Gastroenterol Hepatol. · Pubmed #12525326 No free full text.
This publication has no abstract.
|
| 4 |
Guideline [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001] 2002
Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA, Anonymous00043. · Hospital Universitari Germans Trías i Pujol, Badalona, Barcelona, Spain. · Gastroenterol Hepatol. · Pubmed #11864540 No free full text.
This publication has no abstract.
|
| 5 |
Article Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. free! 2004
Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA, Anonymous00177. · Hospital Universitari Germans Trias i Pujol, Badalona, Spain. · Aliment Pharmacol Ther. · Pubmed #15606397 links to free full text
Abstract: BACKGROUND: Uncontrolled studies suggest that granulocyteaphaeresis might be useful in the management of active ulcerative colitis. AIM: To assess the efficacy of granulocyteaphaeresis treatment in active steroid-dependent inflammatory bowel disease. METHODS: We conducted a multicentre, prospective, open, pilot study in patients with steroid-dependent inflammatory bowel disease. All patients were started on 60 mg/day of prednisone; after 1 week, a five-session programme of granulocyteaphaeresis (once per week) was started. The steroid dose was tapered weekly if there was clinical improvement. Remission was defined as an inactive clinical activity index together with complete withdrawal of steroids at week 6. The patients were followed up for at least 6 months or until disease relapse. RESULTS: Twenty-six patients (14 ulcerative colitis, 12 Crohn's disease) were included. More than a half had been previously treated with immunomodulators. Remission was achieved in 62 and 70% of ulcerative colitis and Crohn's disease, respectively. During a median follow-up of 12.6 months, six of eight ulcerative colitis patients maintained their clinical remission; however, only one Crohn's disease patient remained in remission after the first 6 months of follow-up. CONCLUSIONS: Granulocyteaphaeresis is a safe treatment option in inflammatory bowel disease. A five-session programme of granulocyteaphaeresis seems to be efficient in the treatment of steroid-dependent ulcerative colitis, but not in Crohn's disease.
|
| 6 |
Minor Immunomodulatory therapy for Crohn's disease resulting in acute liver failure. 2004
Reyes J, Moitinho E, Ginard D, Obrador A. · No affiliation provided · Inflamm Bowel Dis. · Pubmed #15626912 No free full text.
This publication has no abstract.
|
|
|